Differential antitumor effects of IgG and IgM monoclonal antibodies and their synthetic complementarity-determining regions directed to new targets of B16F10-Nex2 melanoma cells

Translational Oncology

Volumn 3, Issue 4, 2010, Pages 204-217

  Dobroff, Andrey S ^a,b   Rodrigues, Elaine G ^b   Juliano, Maria A ^b   Friaça, Dayson M ^c   Nakayasu, Ernesto S ^d   Almeida, Igor C ^d   Mortara, Renato A ^b   Jacysyn, Jacqueline F ^c   Amarante Mendes, Gustavo P ^c,e   Magliani, Walter ^f   Conti, Stefania ^f   Polonelli, Luciano ^f   Travassos, Luiz R ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF TEXAS AT EL PASO   (United States)

^e NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY   (Brazil)

^f UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; HISTONE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PHOTOCADHERIN BETA13; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SPECIFICITY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NODULE; MELANOMA; MELANOMA CELL; MOLECULAR RECOGNITION;

EID: 77955684560     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09316     Document Type: Article

References (78)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
2. Terheyden P, Tilgen W, and Hauschild A (2008). Recent aspects of medical care of malignant melanoma. J Dtsch Dermatol Ges 6, 868-878.
3. Komenaka I, Hoerig H, and Kaufman HL (2004). Immunotherapy for melanoma. Clin Dermatol 22, 251-265.
4. Vulink A, Radford KJ, Melief C, and Hart DN (2008). Dendritic cells in cancer immunotherapy. Adv Cancer Res 99, 363-407.
5. Eggermont AM and Schadendorf D (2009). Melanoma and immunotherapy. Hematol Oncol Clin North Am 23, 547-564.
6. Atkins MB (1998). Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am 12, 877-902.
7. Sarkar D, Su ZZ, Park ES, Vozhilla N, Dent P, Curiel DT, and Fisher PB (2008). A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Ther 15, 293-302.
8. Stanglmaier M, Reis S, and Hallek M (2004). Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 83, 634-645.
9. Weiner GJ (2007). Monoclonal antibody mechanisms of action in cancer. Immunol Res 39, 271-278.
10. Kunpeng Z, Yugang W, Jugao C, Yan L, Beifen S, and Yuanfang M (2009). The construction and expression of a novel chimeric anti-DR5 antibody. Hybridoma (Larchmt) 28, 101-105.
11. Gridelli C, Maione P, Ferrara ML, and Rossi A (2009). Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 14, 601-611.
12. Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, et al. (2009). Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 378, 279-284.
13. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, and Livingston PO (2005). Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 174, 5706-5712.
14. McCarron PA, Olwill SA, Marouf WM, Buick RJ, Walker B, and Scott CJ (2005). Antibody conjugates and therapeutic strategies. Mol Interv 5, 368-380.
15. Fleckenstein G, Osmers R, and Puchta J (1998). Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer. Med Oncol 15, 212-221.
16. Colman RW (2002). Inhibition of angiogenesis by a monoclonal antibody to kininogen as well as by kininostatin which block proangiogenic high molecular weight kininogen. Int Immunopharmacol 2, 1887-1894.
17. Yan X, Lin Y, Yang D, Shen Y, Yuan M, Zhang Z, Li P, Xia H, Li L, Luo D, et al. (2003). A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102, 184-191.
18. Song JS, Sainz IM, Cosenza SC, Isordia-Salas I, Bior A, Bradford HN, Guo YL, Pixley RA, Reddy EP, and Colman RW (2004). Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood 104, 2065-2072.
19. Dalle S, Thieblemont C, Thomas L, and Dumontet C (2008). Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 8, 523-532.
20. Ma WWand Adjei AA (2009). Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59, 111-137.
21. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, and Old LJ (1982). GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med 155, 1133-1147.
22. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, and Old LJ (1985). Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82, 1242-1246.
23. Soiffer RJ, Chapman PB, Murray C, Williams L, Unger P, Collins H, Houghton AN, and Ritz J (1997). Administration of R24 monoclonal antibody and lowdose interleukin 2 for malignant melanoma. Clin Cancer Res 3, 17-24.
24. Weber J (2008). Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 13(suppl 4), 16-25.
25. Zigler M, Villares GJ, Lev DC, Melnikova VO, and Bar-Eli M (2008). Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol 9, 307-311.
26. Melnikova VO and Bar-Eli M (2006). Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 19, 395-405.
27. Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L, Gudas JM, Feng X, and Bar-Eli M (2002). Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62, 5106-5114.
28. Shadidi M and Sioud M (2003). Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat 6, 363-371.
29. Apostolopoulos V (2009). Peptide-based vaccines for cancer: are we choosing the right peptides? Expert Rev Vaccines 8, 259-260.
30. Brinkman JA, Fausch SC, Weber JS, and Kast WM (2004). Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 4, 181-198.
31. Miao Y and Quinn TP (2008). Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol Hematol 67, 213-228.
32. Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW, Fritzberg AR, Winkelmann CT, Hoffman T, and Quinn TP (2005). Melanoma therapy via peptide-targeted {alpha}-radiation. Clin Cancer Res 11, 5616-5621.
33. Purcell AW, McCluskey J, and Rossjohn J (2007). More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6, 404-414.
34. Daffre S, Bulet P, Spisni A, Ehret-Sabatier L, Rodrigues EG, and Travassos LR (2008). Bioactive natural peptides. In Studies in Natural Products Chemistry. A-u- Rahman (Ed). Elsevier, Oxford, UK. pp. 597-691.
35. Rodrigues EG, Dobroff AS, Cavarsan CF, Paschoalin T, Nimrichter L, Mortara RA, Santos EL, Fazio MA, Miranda A, Daffre S, et al. (2008). Effective topical treatment of subcutaneous murine B16F10-Nex2 melanoma by the antimicrobial peptide gomesin. Neoplasia 10, 61-68.
36. Polonelli L, Ponton J, Elguezabal N, Moragues MD, Casoli C, Pilotti E, Ronzi P, Dobroff AS, Rodrigues EG, JulianoMA, et al. (2008). Antibody complementaritydetermining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS One 3, e2371.
37. Dobroff AS, Rodrigues EG, Moraes JZ, and Travassos LR (2002). Protective, anti-tumor monoclonal antibody recognizes a conformational epitope similar to melibiose at the surface of invasive murine melanoma cells. Hybrid Hybridomics 21, 321-331.
38. Bouvet JP, Pires R, and Pillot J (1984). A modified gel filtration technique producing an unusual exclusion volume of IgM: a simple way of preparing monoclonal IgM. J Immunol Methods 66, 299-305.
39. Paschoalin T, Carmona AK, Oliveira V, Juliano L, and Travassos LR (2005). Characterization of thimet- and neurolysin-like activities in Escherichia coli M 3 A peptidases and description of a specific substrate. Arch Biochem Biophys 441, 25-34.
40. Stone KL and Williams KR (1996). Enzymatic digestion of proteins in solution and in SDS polyacrylamide gels. In The Protein Protocols Handbook. JM Walker (Ed). Humana Press, Totowa, NJ. pp. 415-425.
41. Jurado JD, Rael ED, Lieb CS, Nakayasu E, Hayes WK, Bush SP, and Ross JA (2007). Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri. Toxicon 49, 339-350.
42. Eng JK, McCormack AL, and Yates JR (1994). An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 5, 976-989.
43. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, and Riccardi C (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139, 271-279.
44. Paschoalin T, Carmona AK, Rodrigues EG, Oliveira V, Monteiro HP, Juliano MA, Juliano L, and Travassos LR (2007). Characterization of thimet oligopeptidase and neurolysin activities in B16F10-Nex2 tumor cells and their involvement in angiogenesis and tumor growth. Mol Cancer 6, 44.
45. Vanhalst K, Kools P, Vanden Eynde E, and van Roy F (2001). The human and murine protocadherin-beta one-exon gene families show high evolutionary conservation, despite the difference in gene number. FEBS Lett 495, 120-125.
46. Morea V, Tramontano A, Rustici M, Chothia C, and Lesk AM (1998). Conformations of the third hypervariable region in the VH domain of immunoglobulins. J Mol Biol 275, 269-294.
47. Levi M, Sallberg M, Ruden U, Herlyn D, Maruyama H, Wigzell H, Marks J, and Wahren B (1993). A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci USA 90, 4374-4378.
48. Drebin JA, Link VC, and Greene MI (1988). Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2, 387-394.
49. Trowbridge IS and Domingo DL (1981). Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 294, 171-173.
50. Miyawaki T, Yachie A, Uwadana N, Ohzeki S, Nagaoki T, and Taniguchi N (1982). Functional significance of Tac antigen expressed on activated human T lymphocytes: Tac antigen interacts with T cell growth factor in cellular proliferation. J Immunol 129, 2474-2478.
51. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, and Mendelsohn J (1984). Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44, 1002-1007.
52. Oren R, Takahashi S, Doss C, Levy R, and Levy S (1990). TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 10, 4007-4015.
53. Hellstrom I, Garrigues HJ, Garrigues U, andHellstrom KE (1990).Highly tumorreactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 50, 2183-2190.
54. Garrigues J, Garrigues U, Hellstrom I, and Hellstrom KE (1993). Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes. Am J Pathol 142, 607-622.
55. Frank M and Kemler R (2002). Protocadherins. Curr Opin Cell Biol 14, 557-562.
56. Wu Q, Zhang T, Cheng JF, Kim Y, Grimwood J, Schmutz J, Dickson M, Noonan JP, Zhang MQ, Myers RM, et al. (2001). Comparative DNA sequence analysis of mouse and human protocadherin gene clusters. Genome Res 11, 389-404.
57. Zhang T, Haws P, and Wu Q (2004). Multiple variable first exons: a mechanism for cell- and tissue-specific gene regulation. Genome Res 14, 79-89.
58. Kasemeier-Kulesa JC, Teddy JM, Postovit LM, Seftor EA, Seftor RE, Hendrix MJ, and Kulesa PM (2008). Reprogramming multipotent tumor cells with the embryonic neural crest microenvironment. Dev Dyn 237, 2657-2666.
59. Oppitz M, Busch C, Schriek G, Metzger M, Just L, and Drews U (2007). Nonmalignant migration of B16 mouse melanoma cells in the neural crest and invasive growth in the eye cup of the chick embryo. Melanoma Res 17, 17-30.
60. Christensen PA, Danielczyk A, Ravn P, Stahn R, Karsten U, and Goletz S (2007). A monoclonal antibody to Lewis Y/Lewis b revealing mimicry of the histone H1 to carbohydrate structures. Scand J Immunol 65, 362-367.
61. KatoM,MochizukiK,KurodaK, Sato S,MurakamiH, YasumotoK,NomotoK, and Hashizume S (1991). Histone H2B as an antigen recognized by lung cancer-specific human monoclonal antibody HB4C5. Hum Antibodies Hybridomas 2, 94-101.
62. Raz E, Ben-Bassat H, Davidi T, Shlomai Z, and Eilat D (1993). Cross-reactions of anti-DNA autoantibodies with cell surface proteins. Eur J Immunol 23, 383-390.
63. Greenberg AH, Chow DA, and Wolosin LB (1983). Natural antibodies: origin, genetics, specificity and role in host resistance to tumours. Clin Immunol Allergy 3, 389-420.
64. Subiza JL, Coll J, Alvarez R, Valdivieso M, and de la Concha EG (1987). IgM response and resistance to ascites tumor growth. Cancer Immunol Immunother 25, 87-92.
65. Gil J, Alvarez R, Vinuela JE, Ruiz de Morales JG, Bustos A, De la Concha EG, and Subiza JL (1990). Inhibition of in vivo tumor growth by a monoclonal IgM antibody recognizing tumor cell surface carbohydrates. Cancer Res 50, 7301-7306.
66. Dadachova E, Revskaya E, Sesay MA, Damania H, Boucher R, Sellers RS, Howell RC, Burns L, Thornton GB, Natarajan A, et al. (2008). Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther 7, 1116-1127.
67. Revskaya E, Jongco AM, Sellers RS, Howell RC, Koba W, Guimaraes AJ, Nosanchuk JD, Casadevall A, and Dadachova E (2009). Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Clin Cancer Res 15, 2373-2379.
68. Magliani W, Conti S,Maffei DL, Ravanetti L, and Polonelli L (2007). Antiidiotypederived killer peptides as new potential tools to combat HIV-1 and AIDS-related opportunistic pathogens. Anti Infective Agents Med Chem 6, 263-272.
69. Magliani W, Conti S, Salati A, Arseni S, Ravanetti L, Frazzi R, and Polonelli L (2004). Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr Med Chem 11, 1793-1800.
70. Magliani W, Conti S, Travassos LR, and Polonelli L (2008). From yeast killer toxins to antibiobodies and beyond. FEMS Microbiol Lett 288, 1-8.
71. Polonelli L, Magliani W, Conti S, Bracci L, Lozzi L, Neri P, Adriani D, De Bernardis F, and Cassone A (2003). Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun 71, 6205-6212.
72. Magliani W, Conti S, Cunha RL, Travassos LR, and Polonelli L (2009). Antibodies as crypts of antiinfective and antitumor peptides. Curr Med Chem 16, 2305-2323.
73. Litman GW, Cannon JP, and Dishaw LJ (2005). Reconstructing immune phylogeny: new perspectives. Nat Rev Immunol 5, 866-879.
74. Bourgeois C, Bour JB, Aho LS, and Pothier P (1998). Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J Virol 72, 807-810.
75. Xu JL and Davis MM (2000). Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13, 37-45.
76. Dorfman T, Moore MJ, Guth AC, Choe H, and Farzan M(2006). A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J Biol Chem 281, 28529-28535.
77. Heap CJ, Wang Y, Pinheiro TJ, Reading SA, Jennings KR, and Dimmock NJ (2005). Analysis of a 17-amino acid residue, virus-neutralizing microantibody. J Gen Virol 86, 1791-1800.
78. Brumatti G, Weinlich R, Chehab CF, Yon M, and Amarante-Mendes GP (2003). Comparison of the anti-apoptotic effects of Bcr-Abl, Bcl-2 and Bcl-XL following diverse apoptogenic stimuli. FEBS Lett 541, 57-63.